Antibacterial activity of grepafloxacin

Journal of Antimicrobial Chemotherapy

Volumn 40, Issue SUPPL. A, 1997, Pages 19-25

  Wiedemann, B ^a   Heisig, P ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GREPAFLOXACIN; OFLOXACIN; QUINOLINE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; CONFERENCE PAPER; GRAM POSITIVE BACTERIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; FLUOROQUINOLONES; HUMANS; PIPERAZINES; QUINOLONES;

EID: 0031446818     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Goss, W. A., Deitz, W. H. & Cook, T. M. (1965). Mechanism of action of nalidixic acid on Escherichia coli. II. Inhibition of deoxyribo-nucleic acid synthesis. Journal of Bacteriology 89, 1068-74.
2. Gellert, M., Mizuuchi, K., O'Dea, M. H., Itoh, T. & Tomizawa, J.-I. (1977). Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proceedings of the National Academy of Sciences of the USA 74, 4772-6.
3. Sugino, A., Peebles, C. L., Kreuzer, K. N. & Cozzarelli, N. R. (1977). Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proceedings of the National Academy of Sciences of the USA 74, 4767-71.
4. Hoshino, K., Kitamura, A., Morrissey, I., Sato, K., Kato, J.-I. & Ikeda, H. (1994). Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrobial Agents and Chemotherapy 38, 2623-7.
5. Khodursky, A. B., Zechiedrich, E. L. & Cozzarelli, N. R. (1995). Topoisomerase IV is a target of quinolones in Escherichia coli. Proceedings of the National Academy of Sciences of the USA 92, 11801-5.
6. Belland, R. J., Morrison, S. G., Ison, C. & Huang, W. M. (1994). Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Molecular Microbiology 14, 371-80.
7. Heisig, P. (1996). Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrobial Agents and Chemotherapy 40, 879-85.
8. Georgiou, M., Muñoz, R., Román, F., Cantón, R., Gómez-Lus, R., Campos, J. & de la Campa, A. G. (1996). Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC. Antimicrobial Agents and Chemotherapy 40, 1741-4.
9. Ferrero, L., Cameron, B., Manse, B., Lagneaux, D., Crouzet, J., Famechon, A. et al. (1994). Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Molecular Microbiology 13, 641-53.
10. Pan, X.-S. & Fisher, L. M. (1996). Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. Journal of Bacteriology 178, 4060-9.
11. Pan, X.-S. & Fisher, L. M. (1997). Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrobial Agents and Chemotherapy 41, 471-4.
12. Paganoni, R., Herzog, C., Braunsteiner, A. & Hohl, P. (1988). Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin. Journal of Antimicrobial Chemotherapy 22, Suppl. D, 3-17.
13. Akiyama, H., Koike, M., Nii, S., Oghuro, K. & Odomi, M. (1991). OPC-17116, an excellently tissue-penetrative new quinolone: pharmacokinetic profiles in animals and antibacterial activities of metabolites. In Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1991. Abstract 1477, p. 345. American Society for Microbiology, Washington, DC.
14. Domagala, J. M. (1994). Structure-activity and structure-side-effect relationships for the quinolone antibacterials. Journal of Antimicrobial Chemotherapy 33, 685-706.
15. Sader, H. S., Erwin, M. E. & Jones, R. N. (1992). In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones. European Journal of Clinical Microbiology and Infectious Diseases 11, 372-81.
16. Mario, F., Jones, R. N., Hoban, D. J., Pignatari, A. C., Yamune, N. & Frei, R. (1994). In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study. Journal of Antimicrobial Chemotherapy 33, 647-54.
17. Hamerschlag, M. R. (1994). Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 38, 1873-8.
18. Barry, A. L. (1992). In vitro activities of OPC-17116 and five other fluoroquinolones. In Program and Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy in Anaheim, CA, 1992. Abstract 779, p. 18. American Society for Microbiology, Washington.
19. Sader, H. S., Jones, R. N., Allen, S. D., Gerlach, E. H., Murray, P. R. & Washington, J. A. (1993). In vitro comparison activity of OPC-17116, a new fluoroquinolone, against more than 5,000 recent clinical isolates from five medical centers. Journal of Chemotherapy 5, 283-8.
20. Fuchs, P. C., Barry, A. L. & Brown, S. D. (1996). Tentative interpretive criteria for testing the susceptibility of Streptococcus pneumonias to eight fluoroquinolones. Diagnostic Microbiology and Infectious Disease 26, 23-7.
21. Pankuch, G. A., Jacobs, M. R. & Appelbaum, P. C. (1995). Activity of CP99,219 compared with DU-6859, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. Journal of Antimicrobial Chemotherapy 35, 230-2.
22. López-Brea, M. & Alarcón, T. (1990). Isolation of fluoroquinolone-resistant Escherichia coli and Klebsiella pneumoniae from an infected Hickman catheter. European Journal of Clinical Microbiology and Infectious Diseases 9, 345-7.
23. Jonsson, M., Walder, M. & Forsgren, A. (1990). First clinical isolate of highly fluoroquinolone-resistant Escherichia coli in Scandinavia. European Journal of Clinical Microbiology and Infectious Diseases 9, 851-3.
24. Lehn, N., Stöwer-Hoffmann, J., Kott, T., Strassner, C., Wagner, H., Krönke, M. et al. (1996). Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance. Journal of Clinical Microbiology 34, 597-602.
25. Heisig, P., Schedletzky, H. & Falkenstein-Paul, H. (1993). Mutations in the gyrA gene of a high-level fluoroquinolone-resistant clinical isolate of Escherichia coli. Antimicrobial Agents and Chemotherapy 37, 696-701.
26. Heisig, P. & Tschorny, R. (1994). Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro. Antimicrobial Agents and Chemotherapy 38, 1284-91.
27. Heisig, P. & Wiedemann, B. (1997). In vitro activity of BAY12-8039 against defined mutants of Escherichia coli and Staphylococcus aureus. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 1997. Abstract F140, p. 169. American Society for Microbiology, Washington, DC.
28. Wakebe, H. & Mitsuhashi, S. (1991). Antibacterial activity of OPC-17116, a new quinolone antimicrobial agent. In Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1990. Abstract 1463, p. 10-11. American Society for Microbiology, Washington, DC.
29. Rustige, C. & Wiedemann, B. (1990). Antibacterial activity of lomefloxacin in a pharmacokinetic in vitro model. Antimicrobial Agents and Chemotherapy 34, 1107-11.
30. Schentag, J. J., Nix, D. E. & Adelman, M. H. (1991). Mathematical examination of dual individualization principles. I: Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP, Annals of Pharmacotherapy 25,1050-7.